

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 7949

Serial No.: 10/562,021

Group Art Unit: 1654

Filed: December 22, 2005

Examiner: Julie Ha

For: CGTase Variants

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

The Examiner's attention is directed to US application no. 11/624,750 (US 2008/0003642). The Examiner in that case rejected that case for double patenting in light of the instant case. A copy of the last rejection in that case is included herewith. Applicants request that the Examiner continuously monitor US application no. 11/624,750 as prosecution continues.

It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: May 7, 2009

/Kristin McNamara, Reg. # 47692/
Kristin J. McNamara, Reg. No. 47,692
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097